{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:09:07Z","timestamp":1791389347678,"version":"4.3.3"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"am","delay-in-days":314,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006967","name":"Center for AIDS Research, Duke University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006967","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DK124276"],"award-info":[{"award-number":["R01DK124276"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007813","name":"Center for AIDS Research, University of Washington","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007813","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000183","name":"Army Research Office","doi-asserted-by":"publisher","award":["W911NF-20-2-0182"],"award-info":[{"award-number":["W911NF-20-2-0182"]}],"id":[{"id":"10.13039\/100000183","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006512","name":"School of Medicine, Duke University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006512","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.biomaterials.2022.121985","type":"journal-article","created":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T08:29:06Z","timestamp":1672734546000},"page":"121985","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["An injectable PEG-like conjugate forms a subcutaneous depot and enables sustained delivery of a peptide drug"],"prefix":"10.1016","volume":"294","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4663-5215","authenticated-orcid":false,"given":"Imran","family":"Ozer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Slezak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5791-3383","authenticated-orcid":false,"given":"Parul","family":"Sirohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6883-1690","authenticated-orcid":false,"given":"Xinghai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Zakharov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0331-5350","authenticated-orcid":false,"given":"Yunxin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0273-6284","authenticated-orcid":false,"given":"Jeffrey I.","family":"Everitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Spasojevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel H.","family":"Collier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"D'Alessio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1569-2228","authenticated-orcid":false,"given":"Ashutosh","family":"Chilkoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biomaterials.2022.121985_bib1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrd2399","article-title":"Protein therapeutics: a summary and pharmacological classification","volume":"7","author":"Leader","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biomaterials.2022.121985_bib2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biomaterials.2022.121985_bib3","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.xphs.2018.01.007","article-title":"Challenges and opportunities for the subcutaneous delivery of therapeutic proteins","volume":"107","author":"Turner","year":"2018","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.biomaterials.2022.121985_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4331\/wjbc.v3.i4.73","article-title":"Pharmacokinetics and toxicology of therapeutic proteins: advances and challenges","volume":"3","author":"Vugmeyster","year":"2012","journal-title":"World J. Biol. Chem."},{"key":"10.1016\/j.biomaterials.2022.121985_bib5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41573-018-0005-0","article-title":"Polymer\u2013drug conjugate therapeutics: advances, insights and prospects","volume":"18","author":"Ekladious","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biomaterials.2022.121985_bib6","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biomaterials.2022.121985_bib7","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar1861","article-title":"Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase","volume":"8","author":"Ganson","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.biomaterials.2022.121985_bib8","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar4500","article-title":"Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients","volume":"16","author":"Hershfield","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.biomaterials.2022.121985_bib9","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1517\/17425247.2012.720969","article-title":"Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents","volume":"9","author":"Garay","year":"2012","journal-title":"Expet Opin. Drug Deliv."},{"key":"10.1016\/j.biomaterials.2022.121985_bib10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000233512","article-title":"Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors","volume":"74","author":"Richter","year":"1984","journal-title":"Int. Arch. Allergy Appl. Immunol."},{"key":"10.1016\/j.biomaterials.2022.121985_bib11","doi-asserted-by":"crossref","first-page":"11804","DOI":"10.1021\/acs.analchem.6b03437","article-title":"Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population","volume":"88","author":"Yang","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.biomaterials.2022.121985_bib12","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.jaci.2015.10.034","article-title":"Pre-existing anti\u2013polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer","volume":"137","author":"Ganson","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.biomaterials.2022.121985_bib13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.22739","article-title":"Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients","volume":"110","author":"Armstrong","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.biomaterials.2022.121985_bib14","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.drudis.2014.08.015","article-title":"Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics","volume":"19","author":"Verhoef","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biomaterials.2022.121985_bib15","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jconrel.2016.06.040","article-title":"Anti-PEG antibodies in the clinic: current issues and beyond PEGylation","volume":"244","author":"Zhang","year":"2016","journal-title":"J. Contr. Release : official journal of the Controlled Release Society"},{"key":"10.1016\/j.biomaterials.2022.121985_bib16","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/bit.21482","article-title":"Size comparison between proteins PEGylated with branched and linear poly(ethylene glycol) molecules","volume":"98","author":"Fee","year":"2007","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.biomaterials.2022.121985_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-016-0002","article-title":"A brush-polymer\/exendin-4 conjugate reduces blood glucose levels for up to five days and eliminates poly(ethylene glycol) antigenicity","volume":"1","author":"Qi","year":"2016","journal-title":"Nature Biomedical Engineering"},{"key":"10.1016\/j.biomaterials.2022.121985_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201801177","article-title":"Architectural modification of conformal PEG-bottlebrush coatings minimizes anti-PEG antigenicity while preserving stealth properties","volume":"8","author":"Joh","year":"2019","journal-title":"Advanced Healthcare Materials"},{"key":"10.1016\/j.biomaterials.2022.121985_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202103672","article-title":"Polyethylene glycol-like brush polymer conjugate of a protein drug does not induce an antipolymer immune response and has enhanced pharmacokinetics than its polyethylene glycol counterpart","author":"Ozer","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.biomaterials.2022.121985_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202107852","article-title":"PEG-like brush polymer conjugate of RNA aptamer that shows reversible anticoagulant activity and minimal immune response","volume":"34","author":"Ozer","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biomaterials.2022.121985_bib21","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1021\/ma500774g","article-title":"Depth analysis on the unusual multistep aggregation process of oligo(ethylene glycol) methacrylate-based polymers in water","volume":"47","author":"Zhang","year":"2014","journal-title":"Macromolecules"},{"key":"10.1016\/j.biomaterials.2022.121985_bib22","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1021\/ma3022376","article-title":"On the thermally reversible dynamic hydration behavior of oligo(ethylene glycol) methacrylate-based polymers in water","volume":"46","author":"Sun","year":"2013","journal-title":"Macromolecules"},{"key":"10.1016\/j.biomaterials.2022.121985_bib23","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.progpolymsci.2016.12.006","article-title":"Non-linear PEG-based thermoresponsive polymer systems","volume":"66","author":"Badi","year":"2017","journal-title":"Prog. Polym. Sci."},{"key":"10.1016\/j.biomaterials.2022.121985_bib24","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1002\/pola.22706","article-title":"Polymerization of oligo(ethylene glycol) (meth)acrylates: toward new generations of smart biocompatible materials","volume":"46","author":"Lutz","year":"2008","journal-title":"J. Polym. Sci. Polym. Chem."},{"key":"10.1016\/j.biomaterials.2022.121985_bib25","doi-asserted-by":"crossref","first-page":"6371","DOI":"10.1021\/ma301303b","article-title":"Aqueous ARGET ATRP","volume":"45","author":"Simakova","year":"2012","journal-title":"Macromolecules"},{"key":"10.1016\/j.biomaterials.2022.121985_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-017-0078","article-title":"One-week glucose control via zero-order release kinetics from an injectable depot of glucagon-like peptide-1 fused to a thermosensitive biopolymer","volume":"1","author":"Luginbuhl","year":"2017","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.biomaterials.2022.121985_bib27","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.3390\/polym11101657","article-title":"Tunable thermo-responsive copolymers from DEGMA and OEGMA synthesized by RAFT polymerization and the effect of the concentration and saline phosphate buffer on its phase transition","volume":"11","author":"Ram\u00edrez-Jim\u00e9nez","year":"2019","journal-title":"Polymers"},{"key":"10.1016\/j.biomaterials.2022.121985_bib28","series-title":"Site-Specific and Stoichiometric Stealth Polymer Conjugates of Therapeutic Peptides and Proteins","author":"Ozer","year":"2016"},{"key":"10.1016\/j.biomaterials.2022.121985_bib29","doi-asserted-by":"crossref","first-page":"10296","DOI":"10.1002\/anie.201604661","article-title":"A modular method for the high-yield synthesis of site-specific protein-polymer therapeutics","volume":"55","author":"Pang","year":"2016","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.biomaterials.2022.121985_bib30","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/anie.201408126","article-title":"A noncanonical function of sortase enables site-specific conjugation of small molecules to lysine residues in proteins","volume":"54","author":"Jayanta","year":"2015","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.biomaterials.2022.121985_bib31","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1039\/c0py00408a","article-title":"Thermoresponsive behaviour of poly[(oligo(ethyleneglycol methacrylate)]s and their protein conjugates: importance of concentration and solvent system","volume":"2","author":"Bebis","year":"2011","journal-title":"Polym. Chem."},{"key":"10.1016\/j.biomaterials.2022.121985_bib32","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrendo.2017.161","article-title":"Animal models of obesity and diabetes mellitus","volume":"14","author":"Kleinert","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.biomaterials.2022.121985_bib33","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.2337\/diabetes.48.5.1026","article-title":"Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob\/ob, db\/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta)","volume":"48","author":"Young","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.biomaterials.2022.121985_bib34","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0169-409X(03)00108-X","article-title":"Pharmacokinetic and biodistribution properties of poly(ethylene glycol)\u2013protein conjugates","volume":"55","author":"Caliceti","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biomaterials.2022.121985_bib35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jphs.2018.08.009","article-title":"C-terminal site-specific PEGylated Exendin-4 analog: a long-acting glucagon like Peptide-1 receptor agonist, on glycemic control and beta cell function in diabetic db\/db mice","volume":"138","author":"Tang","year":"2018","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.biomaterials.2022.121985_bib36","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.neuropharm.2011.12.022","article-title":"The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide","volume":"62","author":"Kanoski","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biomaterials.2022.121985_bib37","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/psb.852","article-title":"Bydureon: long-acting exenatide for once-weekly injection","volume":"23","author":"Ballav","year":"2012","journal-title":"Prescriber"},{"key":"10.1016\/j.biomaterials.2022.121985_bib38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ijpharm.2008.01.015","article-title":"Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration","volume":"356","author":"Gedulin","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biomaterials.2022.121985_bib39","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1208\/s12248-012-9367-0","article-title":"Mechanistic determinants of biotherapeutics absorption following SC administration","volume":"14","author":"Richter","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.biomaterials.2022.121985_bib40","first-page":"655","volume":"vol. 7","author":"Yang","year":"2015"},{"key":"10.1016\/j.biomaterials.2022.121985_bib41","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","article-title":"Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals","volume":"154\u2013155","author":"Kozma","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biomaterials.2022.121985_bib42","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1210\/jc.2010-2822","article-title":"Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with No apparent impact on glycemic response or increased frequency of adverse events: results from the liraglutide effect and action in diabetes (LEAD) trials","volume":"96","author":"Buse","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biomaterials.2022.121985_bib43","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1021\/acs.biomac.7b00443","article-title":"Effect of molecular architecture on cell interactions and stealth properties of PEG","volume":"18","author":"Ozer","year":"2017","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.biomaterials.2022.121985_bib44","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000233309","article-title":"Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins","volume":"70","author":"Richter","year":"1983","journal-title":"Int. Arch. Allergy Appl. Immunol."},{"key":"10.1016\/j.biomaterials.2022.121985_bib45","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/ilar.46.3.280","article-title":"Adjuvants and antibody production: dispelling the myths associated with freund's complete and other adjuvants","volume":"46","author":"Stils","year":"2005","journal-title":"ILAR J."},{"key":"10.1016\/j.biomaterials.2022.121985_bib46","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s13346-013-0176-5","article-title":"Questioning the use of PEGylation for drug delivery","volume":"3","author":"Verhoef","year":"2013","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.biomaterials.2022.121985_bib47","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1208\/s12248-013-9510-6","article-title":"Immunogenicity of subcutaneously administered therapeutic proteins\u2014a mechanistic perspective","volume":"15","author":"Fathallah","year":"2013","journal-title":"AAPS J."},{"key":"10.1016\/j.biomaterials.2022.121985_bib48","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1177\/0192623315591171","article-title":"PEGylated biopharmaceuticals: current experience and considerations for nonclinical development","volume":"43","author":"Ivens","year":"2015","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.biomaterials.2022.121985_bib49","doi-asserted-by":"crossref","first-page":"G26","DOI":"10.1152\/ajpgi.00293.2015","article-title":"Glucagon-like peptide-1 receptor is present in pancreatic acinar cells and regulates amylase secretion through cAMP","volume":"310","author":"Hou","year":"2016","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.biomaterials.2022.121985_bib50","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.nbd.2018.11.023","article-title":"Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury","volume":"124","author":"Bader","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.biomaterials.2022.121985_bib51","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jconrel.2019.03.014","article-title":"Sustained release of exendin-4 from tannic acid\/Fe (III) nanoparticles prolongs blood glycemic control in a mouse model of type II diabetes","volume":"301","author":"He","year":"2019","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2022.121985_bib52","first-page":"229","article-title":"Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes","volume":"7","author":"Mann","year":"2014","journal-title":"Diabetes Metab Syndr Obes"}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961222006251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961222006251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T17:15:38Z","timestamp":1758906938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961222006251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":52,"alternative-id":["S0142961222006251"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121985","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An injectable PEG-like conjugate forms a subcutaneous depot and enables sustained delivery of a peptide drug","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121985","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"121985"}}